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Abstract Specific high-affinity (Kd " 3.4 nM) binding sites for 
~zSI-labelled angiotensin I (p25I]Ang I) were identified on an ep- 
ithelial cell line (IEC-18) derived from the rat small intestine. The 
sites, which also have high affinity for Ang II, are insensitive to 
both AT1- and AT2-specific angiotensin receptor antagonists. The 
rank order of potency with which various angiotensin peptides 
inhibited [12SI]Ang I binding to the cells (Ang I > Ang 
II > Ang(l-7) > [Sar1,11eS]-Ang II > Ang(3-8) > Ang m)  also dis- 
tinguishes these sites from AT~ and AT2 angiotensin receptors. 
;(ey words: Angiotensin I; Atypical angiotensin receptor; 
X_ngiotensin receptor antagonist; IEC-18 cell; Intestinal 
,:pithelium 
antagonists such as PD 123319 and PD 123177 [13-16]. Despite 
differential sensitivities to these antagonists, both AT~ and AT 2 
receptors exhibit high affinity for Ang II, [Sarl,IleS]-Ang II and 
the heptapeptide, angiotensin III (Ang III), whereas they each 
have low affinity for the decapeptide, angiotensin I (Ang I) [16]. 
However, the identification of AT1 and AT2 receptors does 
not exclude the possibility that additional angiotensin receptors 
may also exist. Here, I describe the presence of angiotensin 
binding sites which are pharmacologically distinct from either 
ATt or AT2 angiotensin receptors on IEC-18 rat intestinal 
epithelial cells. 
2. Materials and methods 
~. In~oducfion 
The octapeptide, angiotensin II (Ang II), the principal active 
..:omponent of the renin-angiotensin ystem, plays a major role 
:n the physiology of the cardiovascular system by affecting 
diverse target issues uch as vascular smooth muscle, adrenal 
.;ortex, pituitary and kidney [1]. The peptide also promotes 
• :ardiac hypertrophy and neointimal proliferation following ar- 
'erial injury [2,3], and is implicated in the pathogenesis of hy- 
i)ertension and atherosclerosis [4]. In addition to these cardio- 
vascular effects, Ang II is also active in non-cardiovascular 
issues such as the ovary [5]. 
Multiple mechanisms of signal transduction have been dem- 
mstrated for Ang II. For example, depending on the target cell 
)r tissue, the peptide stimulates phosphoinositide turnover, in- 
fibits adenylate cyclase, activates guanylate cyclase, releases 
)rostaglandins and regulates Ca 2+ channels (reviewed in [6-8]). 
in view of these pleiotrophic actions of Ang II, multiple angio- 
ensin receptor subtypes have been postulated for some years 
9-12]. However, their existence has only been confirmed in 
"ecent years with the introduction of highly-selective non-pep- 
ide antagonists which have allowed a classification of angio- 
ensin receptors into AT1 and AT2 subtypes [13 16]. 
ATm receptors are defined by their sensitivity to biphenylim- 
dazole antagonists such as DuP 753, whereas AT 2 receptors 
ire defined by their sensitivity to tetrahydroimidazopyridine 
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tbetal calf serum; HEPES, N-2-hydroxyethyl-piperazine-N'-2-ethane- 
~ulphonic acid. 
DMEM, foetal calf serum (FCS), trypsin and antibiotics were from 
Sigma. IEC-18 cells (a gift of Dr. A. Quaroni) at passages 30450 were 
maintained at 37°C in DMEM containing 5% (v/v) FCS, insulin (5 
/lg/ml: Novo Nordisk), penicillin (100 U/ml) and streptomycin (100 
pg/ml) in a humidified atmosphere of5% CO2 in air. Cells were subcul- 
tured every 3-4 days using 0.43 mM EDTA/0.05% (w/v) trypsin and 
seeded into plastic dishes or 24-well cluster plates (Nunc) at a dilution 
of 1 : 10. Cells were used after 3-4 days when they formed confluent 
monolayers. Cultures were free from contamination with Myeoplasma 
as determined by staining with 4'-6-diamidino-2'-phenylindole [17].
Angiotensin peptides were from Bachem. Captopril was from Sigma 
and aprotinin was from Bayer. DuP 753 and PD 123319 were supplied 
by DuPont and Parke Davis, respectively, and CGP 42112A was pro- 
vided by Dr. M. deGasparo. Ang I and Ang II were each iodinated 
using the soluble lactoperoxidase method [18] as previously described 
[19], and separated from free iodide using Sep-Pak C j8 cartridges (Wa- 
ters). 
Confluent cell monolayers were washed with ice-cold binding me- 
dium (BM; 130 mM NaCI, 5.1 mM KC1, 1.3 mM CaCI2, 1.3 mM 
MgC12, 0.1 pM KI, 0.1% (w/v) protease-free BSA, 100 U/ml aprotinin, 
1 mM captopril, 50 mM HEPES, pH 7.4) prior to incubation at 4°C 
in BM containing [~:SI]Ang I or [~25I]Ang II, with or without additions, 
as indicated in the individual figure legends. After two washes with 
ice-cold BM, IEC-18 cells were harvested into solubilisation buffer (1% 
(v/v) Triton X-100, 10% (v/v) glycerol, 0.1% (w/v) BSA, 25 mM HEPES, 
pH 7.5), and cell-associated radioactivity was measured in a gamma- 
counter. Non-specific binding was determined in the presence of an 
excess (10 pM) of unlabelled Ang I or Ang II. 
3. Results 
[~25I]Ang I bound specifically and saturably to IEC-18 cells 
at 4°C. Specific binding increased with time to reach a plateau 
value at -4  h (Fig. 1). This incubation time was therefore m- 
ployed in subsequent experiments. 
In principle, the apparent binding of [~25I]Ang I to IEC-18 
cells could have resulted from proteolytic conversion of 
[125I]Ang I to [125I]Ang II during the incubation, with the latter 
(rather than the former) peptide actually binding to the cells. 
In order to exclude this possibility, [125I]Ang I (0.5 nM)-contain- 
ing BM was preincubated with IEC-18 cells and then allowed 
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Fig. 1. Time course of [~I]Ang I binding to IEC-18 cells. Cells were 
incubated for the indicated times at 4°C with [~z5I]Ang I (0.25 nM) in 
the presence or absence of an excess (10 pM) of unlabelled Ang I. After 
washing, the specific binding of [l~SI]Ang I was determined. Each point 
represents he average of duplicate determinations. 
to rebind to a cell line (RIE-1 [19]) known to express AT 1 
receptors (Fig. 2). These cells bind specifically nanomolar con- 
centrations of [125I]Ang II, but not [125I]Ang I. However, when 
[~25I]Ang I was preincubated with IEC-18 cells, no specific bind- 
ing of the radiolabel to RIE-1 cells was subsequently observed 
(Fig. 2). Hence, there was no significant conversion of [125I]Ang 
I to [125I]Ang II during incubation with IEC-18 cells. 
The concentration-dependent binding of [~25I]Ang I to IEC- 
18 cells is shown in Fig. 3. Scatchard analysis of the data (insert 
to Fig. 3) generated a linear slope, indicating the presence of 
a single class of high-affinity [a25I]Ang I binding sites on the cells 
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Fig. 2. Rebinding of [~25I]Ang I to IEC-18 and RIE-1 cells. Binding 
medium containing [J25I]Ang I (0.5 nM) was incubated for 4 h at 4°C 
in the presence (+) or absence (-) of IEC-18 cells. Medium was then 
incubated with fresh cultures oflEC-18 or RIE-1 cells as indicated. The 
total and non-specific binding of the radiolabel to each cell type was 
then determined. Each column represents he mean of triplicate deter- 
minations (+ S.E.M.). 
with a K d value of 3.4 nM and a Bma x of 280 fmol/106 cells 
(which corresponds to 170,000 binding sites per cell, assuming 
one molecule of [125I]Ang I binds per site). 
Unlabelled Ang I inhibited [~25I]Ang I (0.25 nM) binding to 
IEC- 18 cells in a dose-dependent fashion, with an IDs0 of~ 3 nM 
(Fig. 4). However, neither the ATl-specific antagonist, DuP 753 
[13 15], nor the AT2-specific antagonist, PD 123319 [13-15], 
had any effect on [~25I]Ang I binding to IEC-18 cells, even when 
these agents were present at micromolar concentrations (Fig. 
4). In control experiments, DuP 753 inhibited [~25I]Ang II bind- 
ing to RIE-1 cells with an IDs0 o f -30  nM and PD 123319 
inhibited [~25I]Ang II binding to Swiss 3T3 cells (which express 
AT2 receptors [20]) with an IDs0 of ~ 3 nM (data not shown). The 
AT2-specific ligand, CGP 42112 [12], similarly had no effect on 
[~25I]Ang I binding to IEC-18 cells at concentrations up to 10 
/aM (Fig. 4). The angiotensin binding sites on IEC-18 cells are 
therefore atypical, being insensitive to both ATe-, and AT 2- 
specific ligands. 
The potencies with which various angiotensin peptides inhib- 
ited [~25I]Ang I (0.25 nM) binding to IEC-18 cells is shown in 
Fig. 4. It is apparent that, in addition to Ang I, the sites also 
have high affinity (IDa0-5 nM) for Ang II, although this was 
slightly less than that of Ang I (ID50~3 nM). They also have 
moderate affinity (IDs0 ~ 30 riM) for Ang(l 7), but only low affin- 
ity (IDs0- 3BM) for Ang(3 8) and very low affinity (IDs0- 30/aM) 
for Ang III (Fig. 4). The sites also have low affinity (IDs0 ~ 1/aM) 
for the non-specific angiotensin receptor antagonist, [Sar ,Iles] -
Ang II (Fig. 4). Thus, in addition to their insensitivity to ATe- 
and AT2-specific ligands, the rank order of potency with which 
angiotensin peptides inhibit [~25I]Ang I binding (Ang I >- Ang 
II > Ang(1 7) > [Sar~,lle8]-Ang II > Ang(3-8) > Ang III) also 
differentiates the atypical sites on IEC-18 cells from both AT~ 
and AT2 angiotensin receptors (each of which have high affinity 
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Fig. 3. Concentration-dependent bi ding of [~25I]Ang I to IEC-18 cells. 
Cells were incubated for 4 h at 4°C in the presence of [125I]Ang I in the 
concentration range 0.1 11 nM. After removing an aliquot of medium 
for the determination f free [125I]Ang I concentration, specific [125I]Ang 
I binding was determined. The insert shows Scatchard analysis of the 
same data. Each point represents a single determination. 
for Ang II, Ang III and [Sarl,Ile8]-Ang II, but only low affinity 
for Ang I [16]). 
When the experiment of Fig. 4 was repeated using [125I]Ang 
I1 in place of [125I]Ang I, similar results were obtained (Fig. 5). 
[~ ~I]Ang II binding was also insensitive to DuP 753 and PD 
123319, and the rank order of potency with which angiotensin 
p~ptides inhibited [~25I]Ang II binding was Ang I > Ang 
I >> Ang III (Fig. 5). 
4 Discussion 
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To date, there are few reports of high affinity angiotensin 
binding sites that are insensitive to both ATI- and AT2-specific 
a agiotensin receptor antagonists. However, such sites have 
been described on two species of Mycoplasma which commonly 
b~fect eukaryotic cell cultures, namely M. hyorhinis and Achole- 
t lasma laidlawii (although this phenomenon does not appear to 
I-e a general feature of Mycoplasmataceae since atypical sites 
v ere not present on M. hominis) [21,22]. In view of these find- 
i tgs, it is therefore ssential to exclude Mycoplasma infection 
hen evaluating putative atypical angiotensin binding sites on 
altured eukaryotic ells. Accordingly, the IEC-18 cells used in 
1 le present study were free of such contamination as assessed 
1-y staining with 4'-6-diamidino-2'-phenylindole [17] (data not 
lown). 
Atypical angiotensin binding sites have also been described 
~n chick embryo chorioallantoic membrane [23] and turkey 
~drenal gland [24], as well as oocytes [25] and cardiac mem- 
tranes [26] isolated from Xenopus laevis. However, in common 
~'ith the AT~ receptor [16], both the turkey adrenal site and the 
• ~enopus cardiac site have high affinity for Ang II, Ang III and 
[ ~ar ~,Iles]-Ang II, low affinity for Ang I and are able to mediate 
i ~ositol phosphate production and elevation of intracellular 
[2a 2+] [24,26-28]. Since the turkey and Xenopus receptors also 
,qare 60-75% amino acid sequence with the ATI receptor 
[ N,27], it therefore appears likely that they represent the avian 
nd amphibian homologues of the mammalian receptor (which 
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l'ig. 4. Inhibition of [125I]Ang I binding to IEC-18 cells by various 
:,gents. Cells were incubated for 4 h at 4°C in the presence of [~25I]Ang 
I (0.25 nM) and the indicated concentrations ofAng I (o), Ang II (A), 
kng(1-7) (m), [Sar~,IleS]-Ang II (©), Ang(3-8) (z~), Ang III (D), CGP 
42112 (*), PD 123319 (O) or DuP 753 (x). After washing, the specific 
binding of [~25I]Ang I was determined. Each point represents he aver- 
~,ge of duplicate determinations. 
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Fig. 5. Inhibition of [~25I]Ang II binding to IEC-18 cells by various 
agents. Cells were incubated for 4 h at 4°C in the presence of [t25I]Ang 
II (0.25 nM) and the indicated concentrations ofAng I (e), Ang II (A), 
Ang III ([]), PD 123319 (0) or DuP 753 (×). After washing, the specific 
binding of [J25I]Ang I was determined. Each value represents he aver- 
age of duplicate determinations. 
have acquired their unusual pharmacological properties as a 
result of evolutionary divergence). 
Thus far, the only previous report of atypical angiotensin 
binding sites on any mammalian cell is a site present on mouse 
Neuro-2A neuroblastoma cells [29-31]. Like the IEC-18 site, 
the Neuro-2A site also has low affinity for Ang III [29], al- 
though the affinities of this site for Ang I and [Sar~,IleS]-Ang 
II have not been reported. However, it has not been clear 
whether or not the Neuro-2A cells used in these studies were 
contaminated with Mycoplasma, and, if contaminated, which 
strain was present. It therefore remains to be determined 
whether or not the Neuro-2A site is endogenous to those cells, 
and, if so, what its relationship is to the IEC-18 site. 
Recent studies uggest hat some smaller fragments of Ang 
II, particularly Ang(3 8) and Ang(1-7), are also biologically 
active, and that they also act via receptors that are distinct from 
AT~ and AT2 receptors. For example, Ang(3-8) binds to a site 
present in several tissues which is insensitive to both DuP 753 
and PD 123177 [32], and the cardiovascular ctions of Ang(1-7) 
are unaffected by DuP 753 or PD 123319 [33]. 
Although the function, if any, of the atypical site on IEC-18 
cells remains to be determined, its identification supports the 
hypothesis that additional (non-ATe, non-AT2) angiotensin re- 
ceptors also exist. Further characterisation f such receptors 
would be facilitated by the development of antagonists specific 
for each site. Indeed, such an antagonist has recently been 
described for the Ang(l-7) receptor [34]. However, the une- 
quivocal existence of additional 'ATn' receptors will only be 
demonstrated by isolating and sequencing cDNAs encoding 
these putative receptors, 
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